Contractor
AMGEN USA INC
- UEI
- XPGNQMXHP493
- Parent UEI
- Y6NEW42XK544
- Resolved by
- uei
- Confidence
- 1.000
Active from Jan 22, 2021 to Sep 22, 2026.
Sign in to watchRecent awards
| Award | Agency | Place | First action | Current value |
|---|---|---|---|---|
| 36E79725D0009 2 LINE ITEMS CALCITONIN GENE-RELATED PEPTIDES (CGRP) AWARDED FOR A BASE YEAR PERIOD OF 2/26/2025 TO 2/25/2026 PLUS FOUR ONE-YEAR OPTION PERIODS. | Department of Veterans Affairs | — | Jan 13, 2025 | — |
| 36E79725D0053 NEW AWARD FOR TRASTUZUMAB WITH AMGEN. ORDERING PERIOD IS NOV 15, 2025 THROUGH NOV 14, 2026 WITH FOUR ONE-YEAR OPTIONS. | Department of Veterans Affairs | — | Sep 2, 2025 | — |
| 36F79721D0086 65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS, FSS CONTRACT AWARD | Department of Veterans Affairs | — | Jan 22, 2021 | — |
| 75A50122C00065 TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN. | Department of Health and Human Services | CA | Sep 28, 2022 | $839,875,190 |
Sources and method
Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.
Totals sum obligations across every award attributed to this contractor. Obligations are cumulative funding actions, not the value of work delivered.
- 1Awards are attributed by Unique Entity Identifier XPGNQMXHP493, the government's own recipient identifier, not by name matching.
- 2Award records from USAspending.gov, last refreshed Sep 26, 2026.